Molecular structure of Tandutinib, CAS Number: 387867-13-2
Tandutinib (CAS 387867-13-2)
Application:
Tandutinib is A piperazinyl quinazoline receptor tyrosine kinase inhibitor
CAS Number:
387867-13-2
Purity:
≥99%
Molecular Weight:
562.7
Molecular Formula:
C31H42N6O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Tandutinib is a piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of Flt-3/Flk-2 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis. Tandutinib is an inhibitor of PDGFR-beta.
Tandutinib (CAS 387867-13-2) References
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. | DeAngelo, DJ., et al. 2006. Blood. 108: 3674-81. PMID: 16902153
- Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib. | Knesl, P., et al. 2006. Molecules. 11: 286-97. PMID: 17962760
- Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro. | Brownlow, N., et al. 2008. Leukemia. 22: 1452-3. PMID: 18185521
- The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. | Schittenhelm, MM., et al. 2009. Cell Cycle. 8: 2621-30. PMID: 19625780
- P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. | Yang, JJ., et al. 2010. Drug Metab Lett. 4: 201-12. PMID: 20670210
- Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model. | Ohshima-Hosoyama, S., et al. 2012. J Pediatr Hematol Oncol. 34: 116-21. PMID: 22146535
- Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro. | Pfister, C., et al. 2012. Br J Cancer. 107: 1702-13. PMID: 23047550
- Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth. | Ponnurangam, S., et al. 2013. Mol Cancer Ther. 12: 598-609. PMID: 23427297
- Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). | Deng, W., et al. 2013. Oncol Rep. 29: 2479-85. PMID: 23525656
- Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2. | Zhao, XQ., et al. 2013. Eur J Pharm Sci. 49: 441-50. PMID: 23619284
- Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3. | Li, Y., et al. 2019. Eur J Med Chem. 181: 111590. PMID: 31408808
- LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay. | Attwa, MW., et al. 2020. Drug Des Devel Ther. 14: 4439-4449. PMID: 33122888
- Identification and characterization of in vitro, in vivo, and reactive metabolites of tandutinib using liquid chromatography ion trap mass spectrometry. | Al-Shakliah, NS., et al. 2021. Anal Methods. 13: 399-410. PMID: 33410830
Inhibitor of:
c-Kit, Flt-3/Flk-2, PDGFR-beta, and Tyrosine Kinase.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tandutinib, 1 mg | sc-202353 | 1 mg | $84.00 | |||
Tandutinib, 5 mg | sc-202353A | 5 mg | $250.00 |